Trial
NCT00410566
Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Acid Sphingomyelinase Deficiency
Intervention
rhASM
Why stopped
Terminated by sponsor - Single dose safety objective achieved.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-19